Should Undetectable Minimal Residual Disease Be the Goal of Chronic Lymphocytic Leukemia Therapy?

Othman Al-Sawaf, John F. Seymour, Arnon P. Kater, Kirsten Fischer

Research output: Contribution to journalReview article*Academicpeer-review

Original languageEnglish
Pages (from-to)775-791
Number of pages17
JournalHematology/oncology clinics of North America
Issue number4
Early online date2021
Publication statusPublished - Aug 2021


  • CLL
  • Chemoimmunotherapy
  • Chronic lymphocytic leukemia
  • Fixed-duration therapy
  • MRD
  • Minimal residual disease
  • Targeted agents

Cite this